2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 340

Increased Physical Activity in Gout Patients Correlates with Better Prognosis, Decreased Pain, and Suppressed C-Reactive Protein Levels
Abstract Number: 587

Increased Prevalence of Cardiac Disorders in Dutch Ankylosing Spondylitis Patients: The CARDAS Study
Abstract Number: 2457

Increased Prevalence of Systemic Lupus Erythematosus Co-morbidity in Patients with Psoriatic Arthritis: A Population-Based Case-Controlled Study
Abstract Number: 2631

Increased Risk of Acute Coronary Artery Disease and Ischemic Stroke in Patients with Eosinophilic Granulomatosis with Polyangiitis
Abstract Number: 1914

Increased Risk of Progression to Lupus Nephritis for Lupus Patients with Elevated Interferon Signature
Abstract Number: 26

Increased Sodium Accumulation Detected by 23Na-Magnetic Resonance Imaging in Inflamed Knees of Patients with Autoimmune Joint Disease
Abstract Number: 106

Increased T Cell Polyreactivity with Marked Accumulation of TNF-α DP (CD4+CD8+) in the Synovial Tissue of pre-RA, Arthralgia Subjects
Abstract Number: 309

Increasing Capacity and Reducing Costs of Rituximab Administration
Abstract Number: 2693

Increasing Use of Biologics over Time in the First Year After Diagnosis of Systemic JIA Among Patients Enrolled in the Childhood Arthritis & Rheumatology Research Alliance (CARRA) Registry
Abstract Number: 921

Indicators of Actionable Levels of Atherosclerosis in RA Patients Who Appear to Have Low or Intermediate Atherosclerotic Cardiovascular Risk Based on Standard Risk Algorithms
Abstract Number: 2010

Individual Functions of Histone-acetyltransferases CBP and p300 in Regulating Autophagy and Proteasomal Degradation in Synovial Fibroblasts
Abstract Number: 1320

Individual Socio-economic Status and Symptomatic Hip and Knee Osteoarthritis: A Longitudinal Study, Results from the KHOALA Cohort
Abstract Number: 2773

Individually Tailored Predictions of Flare Probability for Rheumatoid Arthritis Patients on Biologic DMARDs Based on Machine Learning Stacking Meta-Classifier
Abstract Number: 1049

Induction of a Profibrotic Phenotype in Normal Dermal Fibroblasts by Expression of PIM1 Kinase and Demonstration of Antifibrotic Effects of Inhibition of PIM Kinases in Systemic Sclerosis Dermal Fibroblasts
Abstract Number: 1729

Infections and Mortality in 230 Childhood Lupus Patients: A Single Center Experience from North India

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].